Axsome Therapeutics
AXSM
398 hedge funds and large institutions have $6.86B invested in Axsome Therapeutics in 2025 Q4 according to their latest regulatory filings, with 86 funds opening new positions, 139 increasing their positions, 122 reducing their positions, and 34 closing their positions.
153% more first-time investments, than exits
New positions opened: 86 | Existing positions closed: 34
86% more funds holding in top 10
Funds holding in top 10: 7 → 13 (+6)
52% more capital invested
Capital invested by funds: $4.51B → $6.86B (+$2.35B)
43% more call options, than puts
Call options by funds: $167M | Put options by funds: $117M
14% more repeat investments, than reductions
Existing positions increased: 139 | Existing positions reduced: 122
12% more funds holding
Funds holding: 355 → 398 (+43)
0.13% more ownership
Funds ownership: 74.53% → 74.66% (+0.13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$66M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$39.5M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$35.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$35.4M |
| 5 |
D.E. Shaw & Co
New York
|
+$35.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$132M |
| 2 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$99M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$61.6M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$53.2M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$38.9M |
AXSM Hedge Fund Activity: Q4 2025 in Review
398 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q4 2025, worth a combined $6.86B — up 52% from $4.51B a quarter earlier.
Buyers outnumbered sellers: 86 funds opened new AXSM positions and 34 closed out — a net gain of 52 holders — while 139 added to existing stakes and 122 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $66M. The largest seller was Macquarie Group, exiting entirely with an estimated $132M sold.
- 398 institutional investors held Axsome Therapeutics (AXSM) as of Q4 2025, up from 355 in Q3 2025.
- Funds reported $6.86B of Axsome Therapeutics stock for Q4 2025, up 52% quarter-over-quarter.
- 86 funds opened new Axsome Therapeutics positions in Q4 2025 and 34 closed out, a net change of +52 holders.
- The largest Axsome Therapeutics buyer in Q4 2025 was T. Rowe Price Associates, an estimated $66M added.
- The largest Axsome Therapeutics seller in Q4 2025 was Macquarie Group, an estimated $132M sold.
Based on aggregated 13F filings for Q4 2025.